High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses

Journal of Virology

Volumn 93, Issue 12, 2019, Pages

  Shen, Liang ^a   Niu, Junwei ^a   Wang, Chunhua ^b   Huang, Baoying ^a   Wang, Wenling ^a   Zhu, Na ^a   Deng, Yao ^a   Wang, Huijuan ^a   Ye, Fei ^a   Cen, Shan ^c   Tan, Wenjie ^a  

^a BEIJING HOSPITAL   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Bioluminescence imaging; Broad spectrum; Coronaviruses; High throughput screening; Inhibitor; Mice

Indexed keywords

ANTIVIRUS AGENT; CHLOROQUINE; EMETINE; LYCORINE; MONENSIN; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PHENAZOPYRIDINE; PYRVINIUM EMBONATE; AMARYLLIDACEAE ALKALOID; PHENANTHRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRUS INFECTION; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; EC50; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN CORONAVIRUS OC43; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LOAD; ANIMAL; CELL LINE; CORONAVIRINAE; DRUG EFFECT; HUMAN; METABOLISM; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PATHOGENICITY; PRECLINICAL STUDY; PROCEDURES; SARS CORONAVIRUS;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CORONAVIRUS; CORONAVIRUS OC43, HUMAN; DRUG EVALUATION, PRECLINICAL; EMETINE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PHENANTHRIDINES; SARS VIRUS;

EID: 85066499191     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00023-19     Document Type: Article

References (66)

1. Saberi A, Gulyaeva AA, Brubacher JL, Newmark PA, Gorbalenya AE. 2018. A planarian nidovirus expands the limits of RNA genome size. PLoS Pathog 14:e1007314. https://doi.org/10.1371/journal.ppat.1007314.
2. Woo PC, Lau SK, Huang Y, Yuen KY. 2009. Coronavirus diversity, phylogeny and interspecies jumping. Exp Biol Med (Maywood) 234:1117-1127. https://doi.org/10.3181/0903-MR-94.
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814-1820. https://doi.org/10.1056/NEJMoa1211721.
4. Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, Lu X, Scherbakova S, Graham RL, Baric RS, Stockwell TB, Spiro DJ, Denison MR. 2010. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog 6:e1000896. https://doi.org/10.1371/journal.ppat.1000896.
5. Pyrc K, Dijkman R, Deng L, Jebbink MF, Ross HA, Berkhout B, van der Hoek L. 2006. Mosaic structure of human coronavirus NL63, one thousand years of evolution. J Mol Biol 364:964 -973. https://doi.org/10.1016/j.jmb.2006.09.074.
6. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. 2016. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24:490-502. https://doi.org/10.1016/j.tim.2016.03.003.
7. de Wit E, van Doremalen N, Falzarano D, Munster VJ. 2016. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523-534. https://doi.org/10.1038/nrmicro.2016.81.
8. Müller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, Sieberg A, Aldabbagh S, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Albarrak AM, Al-Shangiti AM, Al-Tawfiq JA, Wikramaratna P, Alrabeeah AA, Drosten C, Memish ZA. 2015. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis 15:559-564. https://doi.org/10.1016/S1473-3099(15)70090-3.
9. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EK, Fish EN. 2003. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290:3222-3228. https://doi.org/10.1001/jama.290.24.3222.
10. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, Lui SF, Szeto CC, Chung S, Sung JJ. 2003. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348:1986-1994. https://doi.org/10.1056/NEJMoa030685.
11. Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, Siddiqi N, Mushtaq A. 2015. IFN-2a or IFN-1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 70:2129 -2132. https://doi.org/10.1093/jac/dkv085.
12. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimios IE, Kitai I, Mederski BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS, Cescon DW, Poutanen SM, Detsky AS. 2003. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289:2801-2809. https://doi.org/10.1001/jama.289.21.JOC30885.
13. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. 2016. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov 15:327-347. https://doi.org/10.1038/nrd.2015.37.
14. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ. 2014. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:4875-4884. https://doi.org/10.1128/AAC.03011-14.
15. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jr, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. 2014. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58: 4885- 4893. https://doi.org/10.1128/AAC.03036-14.
16. Müller C, Schulte FW, Lange-Grünweller K, Obermann W, Madhugiri R, Pleschka S, Ziebuhr J, Hartmann RK, Grünweller A. 2018. Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picor-naviruses. Antiviral Res 150:123-129. https://doi.org/10.1016/j.antiviral.2017.12.010.
17. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:eaal3653. https://doi.org/10.1126/scitranslmed.aal3653.
18. Shen L, Yang Y, Ye F, Liu G, Desforges M, Talbot PJ, Tan W. 2016. Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene. Antimicrob Agents Chemother 60:5492-5503. https://doi.org/10.1128/AAC.00814-16.
19. Evidente A, Cicala MR, Giudicianni I, Randazzo G, Riccio R. 1983. 1H and 13C NMR analysis of lycorine and -dihydrolycorine. Phytochemistry 22:581-584. https://doi.org/10.1016/0031-9422(83)83051-9.
20. Liu R, Cao Z, Tu J, Pan Y, Shang B, Zhang G, Bao M, Zhang S, Yang P, Zhou Q. 2012. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment Cell Melanoma Res 25: 630-638. https://doi.org/10.1111/j.1755-148X.2012.01036.x.
21. Cho N, Du Y, Valenciano AL, Fernández-Murga ML, Goetz M, Clement J, Cassera MB, Kingston D. 2018. Antiplasmodial alkaloids from bulbs of Amaryllis belladonna Steud. Bioorg Med Chem Lett 28:40-42. https://doi.org/10.1016/j.bmcl.2017.11.021.
22. Bendaif H, Melhaoui A, Ramdani M, Elmsellem H, Douez C, El Ouadi Y. 2018. Antibacterial activity and virtual screening by molecular docking of lycorine from Pancratium foetidum Pom (Moroccan endemic Amaryllidaceae). Microb Pathog 115:138-145. https://doi.org/10.1016/j.micpath.2017.12.037.
23. Chen S, Fang XQ, Zhang JF, Ma Y, Tang XZ, Zhou ZJ, Wang JY, Qin A, Fan SW. 2016. Lycorine protects cartilage through suppressing the expression of matrix metalloprotenases in rat chondrocytes and in a mouse osteoarthritis model. Mol Med Rep 14:3389-3396. https://doi.org/10.3892/mmr.2016.5594.
24. Xu W, Lacerda L, Debeb BG, Atkinson RL, Solley TN, Li L, Orton D, McMurray JS, Hang BI, Lee E, Klopp AH, Ueno NT, Reuben JM, Krishnamurthy S, Woodward WA. 2013. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One 8:e71508. https://doi.org/10.1371/journal.pone.0071508.
25. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P. 2009. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53: 3416-3421. https://doi.org/10.1128/AAC.01509-08.
26. Jacomy H, Talbot PJ. 2003. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology 315:20-33. https://doi.org/10.1016/S0042-6822(03)00323-4.
27. St-Jean JR, Jacomy H, Desforges M, Vabret A, Freymuth F, Talbot PJ. 2004. Human respiratory coronavirus OC43: genetic stability and neu-roinvasion. J Virol 78:8824-8834. https://doi.org/10.1128/JVI.78.16.8824-8834.2004.
28. Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, Chong WK, Hubank M, Plagnol V, Desforges M, Jacques TS, Talbot PJ, Breuer J. 2016. Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med 375:497- 498. https://doi.org/10.1056/NEJMc1509458.
29. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. 2004. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics 113:e73-e76.
30. Cheng VC, Lau SK, Woo PC, Yuen KY. 2007. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 20:660-694. https://doi.org/10.1128/CMR.00023-07.
31. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. 2015. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 28:465-522. https://doi.org/10.1128/CMR.00102-14.
32. Zumla A, Hui DS, Perlman S. 2015. Middle East respiratory syndrome. Lancet 386:995-1007. https://doi.org/10.1016/S0140-6736(15)60454-8.
33. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. 2013. Inhibition of novel coronavirus replication by a combination of interferon-2b and ribavirin. Sci Rep 3:1686. https://doi.org/10.1038/srep01686.
34. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF. 2014. Interferon- and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 9:571-577. https://doi.org/10.1099/vir.0.061911-0.
35. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N. 2004. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 18:719-725. https://doi.org/10.1016/j.bbrc.2004.04.083.
36. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY. 2013. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 67: 606-616. https://doi.org/10.1016/j.jinf.2013.09.029.
37. Shin JS, Jung E, Kim M, Baric RS, Go YY. 2018. Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in vitro. Viruses 10:pii: E283. https://doi.org/10.3390/v10060283.
38. Rabaan AA, Alahmed SH, Bazzi AM, Alhani HM. 2017. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol 66:1261-1274. https://doi.org/10.1099/jmm.0.000565.
39. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR. 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9:e00221-18.
40. Channappanavar R, Lu L, Xia S, Du L, Meyerholz DK, Perlman S, Jiang S. 2015. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J Infect Dis 212:1894 -1903. https://doi.org/10.1093/infdis/jiv325.
41. Niu P, Zhang S, Zhou P, Huang B, Deng Y, Qin K, Wang P, Wang W, Wang X, Zhou J, Zhang L, Tan W. 2018. Ultra-potent human neutralizing antibody repertoires against MERS-CoV from a recovered patient. J Infect Dis 218: 1249-1260. https://doi.org/10.1093/infdis/jiy311.
42. Jiang L, Wang N, Zuo T, Shi X, Poon KM, Wu Y, Gao F, Li D, Wang R, Guo J, Fu L, Yuen KY, Zheng BJ, Wang X, Zhang L. 2014. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 6:234.
43. Lamoral-Theys D, Decaestecker C, Mathieu V, Dubois J, Kornienko A, Kiss R, Evidente A, Pottier L. 2010. Lycorine and its derivatives for anticancer drug design. Mini Rev Med Chem 10:41-50. https://doi.org/10.2174/138955710791112604.
44. Cedrón JC, Gutiérrez D, Flores N, Ravelo AG, Estévez-Braun A. 2010. Synthesis and antiplasmodial activity of lycorine derivatives. Bioorg Med Chem 18:4694-4701. https://doi.org/10.1016/j.bmc.2010.05.023.
45. Toriizuka Y, Kinoshita E, Kogure N, Kitajima M, Ishiyama A, Otoguro K, Yamada H, Omura S, Takayama H. 2008. New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives. Bioorg Med Chem 16:10182-10189. https://doi.org/10.1016/j.bmc.2008.10.061.
46. Hwang YC, Chu JJ, Yang PL, Chen W, Yates MV. 2008. Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay. Antiviral Res 77:232-236. https://doi.org/10.1016/j.antiviral.2007.12.009.
47. Li B, Wang Q, Pan X, Fernández de Castro I, Sun Y, Guo Y, Tao X, Risco C, Sui SF, Lou Z. 2013. Bunyamwera virus possesses a distinct nucleocapsid protein to facilitate genome encapsidation. Proc Natl Acad Sci U S A 110:9048-9053. https://doi.org/10.1073/pnas.1222552110.
48. Gabrielsen B, Monath TP, Huggins JW, Kefauver DF, Pettit GR, Groszek G, Hollingshead M, Kirsi JJ, Shannon WM, Schubert EM, DaRe J, Ugarkar B, Ussery MA, Phelan MJ. 1992. Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod 55:1569-1581. https://doi.org/10.1021/np50089a003.
49. Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L, Zhang X, Hua SN, Yu J, Xiao PG, Li RS, Tan X. 2005. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 67:18-23. https://doi.org/10.1016/j.antiviral.2005.02.007.
50. Liu J, Yang Y, Xu Y, Ma C, Qin C, Zhang L. 2011. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J 8:483. https://doi.org/10.1186/1743-422X-8-483.
51. Guo Y, Wang Y, Cao L, Wang P, Qing J, Zheng Q, Shang L, Yin Z, Sun Y. 2016. A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus. Antimicrob Agents Chemother 60: 913-924. https://doi.org/10.1128/AAC.02274-15.
52. He J, Qi WB, Wang L, Tian J, Jiao PR, Liu GQ, Ye WC, Liao M. 2013. Amaryllidaceae alkaloids inhibit nuclear-to-cytoplasmic export of ribo-nucleoprotein (RNP) complex of highly pathogenic avian influenza virus H5N1. Influenza Other Respir Viruses 7:922-931. https://doi.org/10.1111/irv.12035.
53. Matthews H, Usman-Idris M, Khan F, Read M, Nirmalan N. 2013. Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malar J 12:359. https://doi.org/10.1186/1475-2875-12-359.
54. Low JSY, Chen KC, Wu KX, Ng ML, Chu JJH. 2009. Antiviral activity of emetine dihydrochloride against dengue virus infection. J Antivirals & Antiretrovirals 1:62-71.
55. Chaves Valadão AL, Abreu CM, Dias JZ, Arantes P, Verli H, Tanuri A, de Aguiar RS. 2015. Natural plant alkaloid (emetine) inhibits HIV-1 replication by interfering with reverse transcriptase activity. Molecules 20: 11474-11489. https://doi.org/10.3390/molecules200611474.
56. Khandelwal N, Chander Y, Rawat KD, Riyesh T, Nishanth C, Sharma S, Jindal N, Tripathi BN, Barua S, Kumar N. 2017. Emetine inhibits replication of RNA and DNA viruses without generating drug-resistant virus variants. Antiviral Res 144:196-204. https://doi.org/10.1016/j.antiviral.2017.06.006.
57. MacGibeny MA, Koyuncu OO, Wirblich C, Schnell MJ, Enquist LW. 2018. Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons. PLoS Pathog 14: e1007188. https://doi.org/10.1371/journal.ppat.1007188.
58. Mukhopadhyay R, Roy S, Venkatadri R, Su YP, Ye W, Barnaeva E, Mathews Griner L, Southall N, Hu X, Wang AQ, Xu X, Dulcey AE, Marugan JJ, Ferrer M, Arav-Boger R. 2016. Efficacy and mechanism of action of low dose emetine against human cytomegalovirus. PLoS Pathog 12:e1005717. https://doi.org/10.1371/journal.ppat.1005717.
59. Yang S, Xu M, Lee EM, Gorshkov K, Shiryaev SA, He S, Sun W, Cheng YS, Hu X, Tharappel AM, Lu B, Pinto A, Farhy C, Huang CT, Zhang Z, Zhu W, Wu Y, Zhou Y, Song G, Zhu H, Shamim K, Martínez-Romero C, García-Sastre A, Preston RA, Jayaweera DT, Huang R, Huang W, Xia M, Simeonov A, Ming G, Qiu X, Terskikh AV, Tang H, Song H, Zheng W. 2018. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov 4:31. https://doi.org/10.1038/s41421-018-0034-1.
60. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY. 2015. Treatment with lopinavir/ritonavir or interferon-1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:1904-1913. https://doi.org/10.1093/infdis/jiv392.
61. Alonso-Caplen FV, Matsuoka Y, Wilcox GE, Compans RW. 1984. Replication and morphogenesis of avian coronavirus in Vero cells and their inhibition by monensin. Virus Res 1:153-167. https://doi.org/10.1016/0168-1702(84)90070-4.
62. Niemann H, Boschek B, Evans D, Rosing M, Tamura T, Klenk HD. 1982. Post-translational glycosylation of coronavirus glycoprotein E1: inhibition by monensin. EMBO J 1:1499-1504. https://doi.org/10.1002/j.1460-2075.1982.tb01346.x.
63. Kim JC, Spence RA, Currier PF, Lu X, Denison MR. 1995. Coronavirus protein processing and RNA synthesis is inhibited by the cysteine pro-teinase inhibitor e64dd. Virology 208:1-8. https://doi.org/10.1006/viro.1995.1123.
64. Lu R, Yu X, Wang W, Duan X, Zhang L, Zhou W, Xu J, Xu L, Hu Q, Lu J, Ruan L, Wang Z, Tan W. 2012. Characterization of human coronavirus etiology in Chinese adults with acute upper respiratory tract infection by real-time RT-PCR assays. PLoS One 7:e38638. https://doi.org/10.1371/journal.pone.0038638.
65. Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, Kreher P, Lattwein E, Eschbach-Bludau M, Nitsche A, Bleicker T, Landt O, Schweiger B, Drexler JF, Osterhaus AD, Haagmans BL, Dittmer U, Bonin F, Wolff T, Drosten C. 2012. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 17:20334.
66. Lan J, Yao Y, Deng Y, Chen H, Lu G, Wang W, Bao L, Deng W, Wei Q, Gao GF, Qin C, Tan W. 2015. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2:1438-1446. https://doi.org/10.1016/j.ebiom.2015.08.031.